X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Nicole Longo

Nicole Longo Nicole is senior manager of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Recent Posts

GAO again recommends improvements to 340B program

By Nicole Longo  |    July 11, 2018
Over the years, the non-partisan Government Accountability Office (GAO) has reviewed various aspects of the 340B program, finding areas for improvement and providing recommendations. The latest...   Read More

Celebrating U.S. innovation as USPTO issues the 10 millionth patent

By Nicole Longo  |    June 19, 2018
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for...   Read More

ICYMI - Analysis finds higher outpatient drug spending at 340B hospitals

By Nicole Longo  |    June 18, 2018
Did you know 340B hospitals prescribe more medicines or more expensive medicines? A recent analysis by Milliman, commissioned by PhRMA, found hospitals participating in the 340B drug pricing...   Read More

Supreme Court decisions in two cases pave way for IPR reforms

By Nicole Longo  |    May 31, 2018
At the end of April, the Supreme Court decided two cases concerning the inter partes review (IPR) proceedings enacted as part of the 2011 America Invents Act (AIA). While distinct cases, together...   Read More

Medicare Monday: New Xcenda white paper looks at four strengths of Part B

By Nicole Longo  |    April 30, 2018
In case you missed it, a recent white paper from Xcenda took a deeper look at how Medicare Part B reimburses for physician-administered medicines and how the program has evolved over time. The...   Read More

340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?

By Nicole Longo  |    March 28, 2018
The once little-known 340B drug discount program, which was designed to help low-income, uninsured or otherwise vulnerable patients access prescription medicines at safety-net facilities, is now a...   Read More

Medicare Monday: Moran finds Part B medicine prices are stable, not a key driver of Medicare costs

By Nicole Longo  |    March 26, 2018
Earlier this year, we examined research that shows Part B spending continues to be a small, stable share of overall Medicare spending. Today, we’re looking at the trends in Average Sales Price...   Read More

What is inter partes review and why does it matter?

By Nicole Longo  |    March 16, 2018
For more than three decades Hatch-Waxman (the Drug Price Competition and Patent Term Restoration Act of 1984) has encouraged innovation in biopharmaceutical development while at the same time...   Read More

340B Spotlight: Hospital system adds voice to comments about flawed 340B program

By Nicole Longo  |    February 2, 2018
Each week, more and more groups are calling attention to the 340B program and its myriad problems. Here’s a quick recap of some of the latest voices out there.   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates